Emulate Revenue, Valuation, Funding & Investors

Jagsonpal Pharmaceuticals Ltd is a pharmaceutical company. It develops and manufactures active pharmaceutical ingredients and formulations like Capsule and Tablet. The company operates in the Gynaecology, Orthopaedics, Dermatology and Paediatric segments. Its brands comprise Lycored, Maintane, Doxypal DR, and others.

Shape Therapeutics is a Seattle-headquartered biotechnology company pioneering RNA editing and gene therapy platforms. Its technologies address neurodegenerative disorders, metabolic conditions, and rare genetic diseases through advanced payloads, delivery systems, and manufacturing processes.

Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. The company is engaged in the development, manufacture, and commercialization of high-quality biologics in China and around the world. It focuses on areas such as oncology, metabolism, autoimmunity, metabolism, and ophthalmology. Geographically company's revenue is generated from customers located in Mainland China.

Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).

Medeze Group PCL is engaged in the business of providing stem cell storage, analyzing, isolation, cultivation and preservation services for medical use. It is organised into four reportable segments: Stem cell sample collection service segment; White blood cell potential testing service segment; Other services segment and Sales of products segment. Geographically, the company operates in Thailand, Vietnam, Cambodia, Philippines, and Other countries, of which maximum revenue is derived from Thailand.

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.